Abstract: The present invention provides compositions comprising cannabinoids and/or cannabinoid analogs and processes for producing the same.

Abstract: The present invention provides pharmaceutical compositions comprising solid nanoparticles, wherein the solid nanoparticles comprise i) an effective amount of a therapeutically active agent, wherein the therapeutically active agent is a substantially water insoluble prodrug; and ii) a biocompatible polymer.

Abstract: The present invention provides a composition comprising solid nanoparticles wherein the solid nanoparticles comprise i) an effective amount of a first therapeutically active agent; ii) an effective amount of one or more additional therapeutically active agents; and iii) a biocompatible polymer wherein the one or more additional therapeutically active agents is sufficiently miscible with the first therapeutically active agent to form solid particles, wherein the particles comprise a substantially single-phase mixture of the first therapeutically active agent and the one or more additional therapeutically active agents.

Abstract: The invention provides a composition comprising microparticles of a water-insoluble or poorly soluble compound, at least one phospholipid, and at least one surfactant, produced by applying an energy to a mixture comprising particles of the compound, the at least one phospholipid, and the at least one surfactant so as to obtain the microparticles. The invention also provides a process for preparing microparticles of a water-insoluble or poorly soluble compound. The process includes mixing particles of a water-insoluble or poorly soluble compound with at least one phospholipid and at least surfactant to form a mixture and applying energy to the mixture sufficient to produce microparticles of the compound. The methods of the invention allow for the production of microparticles smaller than particles produced through previously known methods and the microparticles exhibit advantageous properties including remarkable resistance to particle size growth during storage.

Abstract: The invention provides a composition comprising microparticles of a water-insoluble or poorly soluble compound, at least one phospholipid, and at least one surfactant, produced by applying an energy to a mixture comprising particles of the compound, the at least one phospholipid, and the at least one surfactant so as to obtain the microparticles. The invention also provides a process for preparing microparticles of a water-insoluble or poorly soluble compound. The process includes mixing particles of a water-insoluble or poorly soluble compound with at least one phospholipid and at least surfactant to form a mixture and applying energy to the mixture sufficient to produce microparticles of the compound. The methods of the invention allow for the production of microparticles smaller than particles produced through previously known methods and the microparticles exhibit advantageous properties including remarkable resistance to particle size growth during storage.

Abstract: A substantially sterile extract of Nerium species is described, together with a method for production thereof. A pharmaceutical composition comprising the extract is also described, together with a method for production thereof. The pharmaceutical composition is useful for the treatment of cell-proliferative and immune deficient diseases in mammals, including cancer and AIDS, respectively.

Abstract: A substantially sterile extract of Nerium species is described, together with a method for production thereof. A pharmaceutical composition comprising the extract is also described, together with a method for production thereof The pharmaceutical composition is useful for the treatment of cell-proliferative and immune deficient diseases in mammals, including cancer and AIDS, respectively.

Abstract: Pharmaceutical compositions containing cyclosporin microparticles are prepared by applying energy to cyclosporin particles in the presence of phospholipid and one or more surface modifiers. These microparticles consist essentially of cyclosporin, a phospholipid and at least one surface modifier. The surface modifier or surface modifiers yield particles of a volume-weighted mean particle size the cyclosporin about 50% smaller than cyclosporin particles produced in the presence of a phospholipid only and without the presence of the surface modifier using the same energy input.

Abstract: Hydrothermal BaTiO3 crystallites were coated with Bismuth solutions prepared from Bismuth metal-organics and anhydrous solvents. The Bismuth metal-organics were Bi 2-ethylhexanoate and Bi-neodecanoate. Bismuth oxide was also used as a comparison to the Bismuth solutions. BaTiO3 ceramics with either 3.0 wt % equivalent Bismuth oxide or 5.0 wt % equivalent Bismuth oxide were made by sintering the compacts between 700° C. and 1000° C. BaTiO3 ceramics that were coated by Bi-neodecanoate densified >90% theoretical as low as 800° C. for 3.0 wt % equivalent Bi2O3. Average grain sizes of 0.2-0.4 &mgr;m were observed for Bi-coated BaTiO3 ceramics, for sintering temperatures below 950° C. Dielectric K versus temperature measurements of Bismuth-coated BaTiO3 ceramics, sintered in the lower temperature ranges, showed consistently superior dielectric characteristics.

Abstract: Submicron size particles of pharmaceutical or other water-insoluble or poorly water-insoluble substances are prepared using a combination of one or more surface modifiers/surfactants such as polaxomers, poloxamines, polyoxyethylene sorbitan fatty acid esters and the like together with natural or synthetic phospholipids. Particles so produced have a volume weighted mean particle size at least one-half smaller than obtainable using a phospholipid alone. Compositions so prepared are resistant to particle size growth on storage.